Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.48 |
| ▸ | MMEL1 | Q495T6 | 7/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935618 | 0.80 | MME (0.66) | MMEACEMMEL1TAAR1 | |
| SCHEMBL9935638 | 0.80 | MME (0.66) | MMEACEMMEL1TAAR1 | |
| SCHEMBL28023714 | 0.79 | MME (0.39) | MMEADRB3ADRB1 | |
| SCHEMBL27932200 | 0.75 | MME (0.37) | MMEACE | |
| SCHEMBL27913976 | 0.75 | MME (0.39) | MMEACE | |
| SCHEMBL27913955 | 0.73 | MME (0.39) | MME | |
| SCHEMBL27913953 | 0.73 | MME (0.58) | MME | |
| SCHEMBL9934656 | 0.72 | MME (0.53) | MMEACEMMEL1TAAR1 | |
| SCHEMBL9934642 | 0.72 | MME (0.53) | MMEACEMMEL1TAAR1 | |
| SCHEMBL16458036 | 0.72 | MME (0.51) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.